8 results about "Phosphatidyl inositol" patented technology

The present invention relates to a method of reducing the phospholipid content in an oil or fat composition and polypeptides having PI-specific phospholipase C activity as well as polypeptides having PC, PE-specific phospholipase C activity and combinations thereof capable of catalyzing this reduction. The invention also relates to polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Provided is a simple and specific means for detecting Listeria monocytogenes and / or Listeria ivanovii. A culture medium for detecting Listeria monocytogenes and / or Listeria ivanovii contains the following components (A), (B), and (C): (A) a chromogenic substance that develops color by being decomposed with β-glucosidase or a fluorogenic substance that emits fluorescence; (B) a chromogenic substance that develops color by being decomposed with phosphatidylinositol-specific phospholipase C or a fluorogenic substance that emits fluorescence; and (C) a sugar.

This invention, through lipidomics and clinical sample validation, found that prospective follow-up of pre-pregnancy serum samples from women with a history of recurrent pregnancy loss (RPL) revealed that the pre-pregnancy serum levels of phosphatidylinositol PI (18:1 / 18:1) (i.e., PI 36:2), phosphatidylcholine (29:0-6:0) (i.e., PC 35:0), phosphatidylethanolamine (18:1p-18:2) (i.e., PE 36:3p), triglycerides (28:1-10:4-11:2) (i.e., TG 49:7), triglycerides (14:0-18:2-20:5) (i.e., TG 52:7), and wax esters (22:1) (i.e., WE 22:1) were significantly lower in these women than in those who subsequently achieved successful pregnancies. This confirms that the pre-pregnancy serum levels of these six lipids (PI 36:2, PC 35:0, PE 36:3p, TG 49:7, TG 52:7, WE 22:1) were significantly lower in these women than in those who subsequently achieved successful pregnancies. Decreased levels of 22:1 lipids were significantly associated with the risk of miscarriage in subsequent pregnancies. The area under the curve (AUC) of the predictive model constructed by combining six lipids reached 0.85, demonstrating good predictive efficacy. Based on these findings, this lipid combination can serve as a reliable predictor of miscarriage risk in subsequent pregnancies in RPL patients and can be used to develop diagnostic reagents or kits for preconception risk screening.

This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), lerociclib, abemaciclib (Vorzenio), trilaciclib, lerociclib), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and / or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound and a cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor.

The present application belongs to the technical field of yeast extract, and particularly relates to a yeast phospholipid and a preparation method thereof. The preparation method of the yeast phospholipid comprises the following steps: (1) dispersing yeast raw materials in an alcohol solution, then performing solid-liquid separation to obtain an extraction solution; (2) concentrating the extraction solution, then dispersing the extraction solution in an extraction solvent to perform extraction, separation, and concentrating a heavy phase solution to obtain the yeast phospholipid. In terms of the total mass of the yeast phospholipid, the crude fat contains 10% to 40% of phosphatidylcholine, 10% to 30% of phosphatidylethanolamine, and 1% to 10% of phosphatidylinositol. The preparation method of the present application extracts yeast raw materials by using a single solvent, is convenient for recovery, reduces the extraction cost, has higher extraction efficiency of the obtained phospholipid, has higher contents of phosphatidylcholine, phosphatidylethanolamine and phosphatidylinositol, has higher content of unsaturated fatty acids, and is suitable for industrialized production.

The invention discloses a starch film slow-release patch for promoting wound healing and a preparation method thereof.The method comprises the steps that 1, silymarin, centella asiatica extract, aescin, aloe polysaccharide, lithospermum erythrorhizon extract, olive oil, lecithin and cetostearyl alcohol polyether are taken and mixed to be uniform, phosphatidylinositol and deionized water are added, low-speed stirring and high-speed shearing are conducted in sequence at the temperature of 25-35 DEG C, and the starch film slow-release patch for promoting wound healing is obtained; the microcrystal nano-emulsion is obtained; 2, adding gelatin and starch into deionized water, heating for 5-15 minutes at 60-80 DEG C while stirring, cooling to 40-50 DEG C, adding citric acid, calcium citrate, glycerol, ethylene glycol and the crystal nano-emulsion, and uniformly mixing to obtain mixed paste liquid; 3, the mixed paste liquid is contained in a vacuumizing container, vacuumizing is conducted, and degassed mixed paste liquid is obtained; 4, carrying out roll forming on the mixed paste to obtain a starch film; and 5, cutting the starch film into the starch film slow-release patch. The starch film sustained-release patch prepared by the invention has good flexibility, viscosity and air permeability, and is capable of stopping bleeding, resisting inflammation and promoting wound healing.

The application provides a traditional Chinese medicine preparation for improving myopia, a gel base and a preparation method thereof. The traditional Chinese medicine preparation for improving myopia comprises the gel base, a traditional Chinese medicine extract; the gel base comprises a drug carrier, a gel skeleton and a pharmaceutical excipient; the drug carrier is a complex formed by cationic cyclodextrin and phosphatidylinositol; the gel skeleton is obtained by crosslinking sodium polyacrylate and gallium hydroxyaluminum; and the pharmaceutical excipient comprises hydroxypropyl methylcellulose, polyvinyl alcohol, hyaluronic acid and glycerol. The traditional Chinese medicine preparation for improving myopia can effectively improve myopia and has the characteristics of high encapsulation efficiency and good stability.